- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Jordan's Hikma to Make Mark in US with Roxane Laboratories Acquisition
July 28, 2015.
Jordanian drugmaker Hikma Pharmaceuticals Plc has agreed to buy Boehringer Ingelheim GmbH’s Roxane business for $2.65 billion to become the sixth-largest supplier of generic medicines in the U.S, Bloomberg reports. Hikma, founded in Amman, Jordan, in 1978, said the deal should close in Q4 and boost earnings from next year. Roxane’s manufacturing plant in Columbus, Ohio, will bring new technologies and capabilities to Hikma, including the ability to make solids, liquids, nasal sprays and dry powder inhalers. Boehringer will hold about 16.7 percent of Hikma after the new shares are issued, Bloomsberg reports. http://www.bloomberg.com/news/articles/2015-07-28/hikma-to-buy-roxane-from-boehringer-ingelheim-for-2-65-billion
